Prospective Comparative Evaluation of Flow Cytometric Scores Regarding the Sensitivity and Specificity As Well As Prognosis in 616 Patients with Proven or Suspected MDS
Uta Oelschlaegel(University Hospital Carl Gustav Carus), Uwe Platzbecker(National Center for Tumor Diseases), Martin Bornhäuser(Technische Universität Dresden), Lorenz Oelschlaeger(University Hospital Carl Gustav Carus), Katja Sockel(Innsbruck Medical University), Brigitte Mohr(Klinik und Poliklinik für Psychotherapie und Psychosomatik)
Cited by 0
Related Papers
Retinoic Acid and Arsenic Trioxide for Acute Promyelocytic Leukemia
|New England Journal of Medicine|2013|1.6k
Management of acute promyelocytic leukemia: updated recommendations from an expert panel of the European LeukemiaNet
|Blood|2019|655
Addition of sorafenib versus placebo to standard therapy in patients aged 60 years or younger with newly diagnosed acute myeloid leukaemia (SORAML): a multicentre, phase 2, randomised controlled trial
|The Lancet Oncology|2015|402